Linked Life Data

9755805

Source:http://linkedlifedata.com/resource/pubmed/id/9755805

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1998-10-21
pubmed:abstractText
As a result of tamoxifen becoming the first endocrine compound with proven activity in breast cancer, a. broad spectrum of new substances have been tested and several are now available for clinical use. New pure antiestrogens show no estrogenic activity as a result of different receptor binding, and some other derivatives of tamoxifen demonstrate varied toxicity profiles. The second and third generation of aromatase inhibitors can selectively inhibit the aromatase enzyme in the peripheral tissue and perhaps even in tumor cells. Gonadotrophin-releasing hormone (GnRH)-analogues can suppress ovarian function in premenopausal patients and thus prevent surgical ovarectomy. The value of a new group of anti-progestional substances has not yet been clarified. In this overview the most important compounds are reviewed for efficacy and toxicity in breast cancer patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0753-3322
pubmed:author
pubmed:issnType
Print
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
122-32
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
New endocrine approaches in the treatment of breast cancer.
pubmed:affiliation
Dept of Obstetrics and Gynecology, University of Frankfurt, Germany.
pubmed:publicationType
Journal Article, Review